We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.
- Authors
Pipas, J M; Zaki, B I; McGowan, M M; Tsapakos, M J; Ripple, G H; Suriawinata, A A; Tsongalis, G J; Colacchio, T A; Gordon, S R; Sutton, J E; Srivastava, A; Smith, K D; Gardner, T B; Korc, M; Davis, T H; Preis, M; Tarczewski, S M; MacKenzie, T A; Barth, R J, Jr
- Abstract
Neoadjuvant therapy has been investigated for localized and locally advanced pancreatic ductal adenocarcinoma (PDAC) but no standard of care exists. Combination cetuximab/gemcitabine/radiotherapy demonstrates encouraging preclinical activity in PDAC. We investigated cetuximab with twice-weekly gemcitabine and intensity-modulated radiotherapy (IMRT) as neoadjuvant therapy in patients with localized or locally advanced PDAC.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 11, p2820
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mds109